The role of OPG as a potential biomarker in STEMI patients to identify patients with risk of adverse remodeling and HF development seems to be limited by a strong association with age, confounding effect of heparin administration, and little additive value to well-established biomarkers such as Troponin T, NT-pro-BNP and CRP. The gene discussed is CRP; the disease is hydrops fetalis.